Literature DB >> 31934147

Identification of a novel pre-terminating mutation in human HBB gene as a cause of β0-thalassemia phenotype.

Liangpu Xu1, Meihuan Chen1, Hailong Huang1, Na Lin1, Lingji Chen1, Yan Wang1, Min Zhang1, Deqin He1, Yuan Lin1.   

Abstract

Beta (β)-thalassemia (thal) is one of the most common genetic disorders of hemoglobin synthesis worldwide. Most cases of β-thal are caused by point mutations in hemoglobin subunit beta (HBB) gene, and only a minority of cases are caused by missing mutations of HBB gene. In this study, a 31-year-old pregnant woman with a typical thal phenotype was admitted at Fujian Provincial Maternity and Children's Hospital for prenatal diagnosis. Her father also presented with a typical thal phenotype, while the other members in the proband family were normal. Interestingly, Gap-PCR and reverse dot-blot hybridization assays showed that no mutation was found in the human HBA and HBB genes of the proband and her father. Subsequently, Sanger DNA sequencing identified a novel pre-terminating mutation, c.271 G>T [CD90 (GAG>TAG, Glu→stop codon)], in HBB gene from the proband and her father, while the other members in the proband family were normal. This mutation created a stop codon at amino acid 90 in exon 2 coding sequences of HBB gene, and led to a β0-thal phenotype. In summary, the present study is, to the best of our knowledge, the first to report a pre-terminating mutation, c.271 G>T [CD90 (GAG>TAG, Glu→stop codon)], in human HBB gene as a cause of β0-thal phenotype. This is important for clarifying the molecular mechanism of β0-thal and is useful for genetic counseling and prenatal screening. IJCEP
Copyright © 2019.

Entities:  

Keywords:  HBB; gene; mutation; phenotype; β-thal

Year:  2019        PMID: 31934147

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  1 in total

1.  Characterization of a novel HBB:c.194dup variant of the β-globin gene combined with six alpha genes.

Authors:  Jungao Huang; Le Ding; Junkun Chen; Shiping Chen; Peirun Tian; Jun Xie; Xiaoyan Huang; Xiaoqin Xin
Journal:  J Int Med Res       Date:  2022-05       Impact factor: 1.573

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.